glp 1 gip vs glp 1 Free Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes 🔗 Link in bio #FOAMed #Type2Diabetes #GLP1 Targeting GLP-1, GIP & GCG

Background Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM)

Purpose of Review This review provides a comprehensive and scholarly examination of glucagon-like peptide-1 receptor (GLP-1R) agonists, tracing their evolution from glycemic control agents in diabetes mellitus (DM) to multifaceted therapeutics with expanding indications in cardiovascular, renal, and metabolic health

Compounding pharmacies and investors have brought legal challenges to enjoin the FDA from enforcing the changes to the shortage list, but have so far been unsuccessful

We recommended using GLP-1 Boost for 4-6 months

Grading of Recommendations Assessment, Development and Evaluation (GRADE) showed moderate certainty for MACE, all-cause death and hospitalization for HF

Diabetesmellitus (DM) is a group of metabolic diseases classified by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both